Back to search
Nonfunctional Pancreatic Neuroendocrine Tumor
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Nonfunctional Pancreatic Neuroendocrine Tumor trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Nonfunctional Pancreatic Neuroendocrine Tumor trials you may qualify forThis phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may h…
The aim of the study is to evaluate the most appropriate management of sporadic asymptomatic non-functioning pancreatic neuroendocrine neoplasms (NF-PNEN) ≤ 2 c…
This study aims to quantify the malignant potential of non-functional neuroendocrine tumors of the pancreatic body and tail ≤ 3 cm by collecting real-world data…
Pancreatic Neuroendocrine Neoplasms (PanNEN) are a heterogeneous group of neoplasms that arise from the endocrine cells of the pancreatic gland. Non-functioning…
The current study aims to access the feasibility, safety, and efficacy of EUS-FNI for nonfunctional pNETs
This phase II trial studies how well ribociclib works in treating patients with neuroendocrine tumors of the foregut, which includes the thymus, lung, stomach,…
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroend…
Chromogranin A (CgA) is a glycoprotein with a molecular weight of 49 to 52 kDa produced by chromaffin cells of the adrenal medulla, enterochromaffin-like (ECL)…
Predicting aggressive behavior in the group of nonfunctional pancreatic neuroendocrine tumors (NF P-NET) remains a difficult problem in clinical practice. At pr…